148
Views
5
CrossRef citations to date
0
Altmetric
Research Article

3A4, a new potential target for B and myeloid lineage leukemias

, , , &
Pages 797-804 | Received 11 Oct 2010, Accepted 14 Mar 2011, Published online: 20 Apr 2011

References

  • Akifusa S, Heywood W, Nair SP, Stenbeck G, Henderson B. (2005). Mechanism of internalization of the cytolethal distending toxin of Actinobacillus actinomycetemcomitans. Microbiology (Reading, Engl), 151, 1395–1402.
  • Beckman I, Shepherd K, Dimopoulos K, Ahern M, Firgaira F, Bradley J. (1994). Differential expression and regulation of cytokine mRNAs in normal human CD45R T cell subsets. Cytokine, 6, 116–123.
  • Brod SA, Rudd CE, Purvee M, Hafler DA. (1989). Lymphokine regulation of CD45R expression on human T cell clones. J Exp Med, 170, 2147–2152.
  • Bunjes D. (2002). 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma, 43, 2125–2131.
  • Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN. (2001). Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood, 98, 565–572.
  • Chao TC, Walter RJ, Greager JA. (1997). Binding and internalization of anti-sarcoma IgG and IgM antibodies. J Surg Res, 70, 27–33.
  • Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. (2005). Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol, 23, 4110–4116.
  • Ferrari M, Fornasiero MC, Isetta AM. (1990). MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods, 131, 165–172.
  • Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B, Berrie E, Bird P, Hale G, Blumstein NM, Waldmann H, Bunjes D, Reske SN. (2006). Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med, 47, 1335–1341.
  • Hermiston ML, Xu Z, Weiss A. (2003). CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol, 21, 107–137.
  • Holmes N. (2006). CD45: all is not yet crystal clear. Immunology, 117, 145–155.
  • Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–497.
  • Kulkarni PN, Blair AH, Ghose TI. (1981). Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res, 41, 2700–2706.
  • Li JL, Cai YC, Liu XH, Xian LJ. (2006). Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs, 17, 307–314.
  • Li S, Tang Y. (2010). Accurate determination of internalization for target binding antibody using papain digestion and flow cytometry. Hybridoma (Larchmt), 29, 133–139.
  • Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD. (2007). Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem Toxicol, 45, 1678–1687.
  • Marshall JD, Eveland WC, Smith CW. (1958). Superiority of fluorescein isothiocyanate (Riggs) for fluorescent-antibody technique with a modification of its application. Proc Soc Exp Biol Med, 98, 898–900.
  • Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW. (1995). Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood, 85, 1122–1131.
  • Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FR. (2009). Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 114, 5444–5453.
  • Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW. (2003). Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood, 101, 2340–2348.
  • Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, Mao YQ, Kan B, Lei S, Wang GS, Jiang Y, Wang QR, Luo F, Zou LQ, Liu JY. (2002). Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol, 128, 223–230.
  • Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. (2005). CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant, 35, 1127–1132.
  • Sorensen RU, Kallick MD. (1988). Clinical uses of intravenous immune globulin: immunoglobulin replacement therapy and treatment of autoimmune cytopenias. J Clin Apher, 4, 97–103.
  • Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother, 5, 213–226.
  • The TH, Feltkamp TE. (1970). Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology, 18, 875–881.
  • Vernier J, Jarrossay D, Agthoven AV. (2002). Non-lineage antigen blind panel: biochemical analysis report. In: Leucocyte Typing VII, Mason D et al (Eds). Oxford University Press, New York, pp. 453–461.
  • Xu XJ, Tang YM, Song H, Yang SL, Shi SW, Wei J. (2010). Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children’s hospital in China. Leuk Lymphoma, 51, 2262–2269.
  • Yao TJ, Scheinberg DA. (2000). Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res, 6, 372–380.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.